Zhendong Chen

机构：Zhejiang Normal University, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University · ORCID：0000-0001-7481-3985

发表论文 104 篇 · 总被引 3345 次 · h-index 24

代表论文

• Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study. (2024 · Journal of Clinical Oncology · 被引 35)
• Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial (2024 · Med · 被引 33)
• Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in Phase 2 study (2024 · Cancer Research · 被引 19)
• SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer (2024 · Cancer Immunology Immunotherapy · 被引 15)
• Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study (2024 · Therapeutic Advances in Medical Oncology · 被引 14)
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial (2025 · Nature Communications · 被引 11)